{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:49:27Z","timestamp":1790426967301,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sustained virologic response rates have increased dramatically following direct acting antiviral (DAA) therapy in chronic HCV infection. However, resistance-associated substitutions (RASs) may occur either prior to DAA or following drug exposure. The aim of this study was to determine RASs in DAA treatment-failing patients and the role of RASs in failure treatment. Six hundred and twenty HCV patients were evaluated. Direct sequencing of HCV genes was performed at breakthrough in all 31 patients failing DAAs, and in 19 baseline patients. Deep sequencing analysis was performed in 15\/19 baseline patients. RASs were detected at breakthrough in 17\/31 patients and at baseline in 11\/19 patients, although, only 8\/19 patients carried RASs associated with the prescribed regimen. Deep sequencing analysis showed RASs at baseline in 10\/15 treatment-failing patients. No significant difference was observed with the Sanger sequencing. Treatment failure in the 14\/31 patients without RASs was associated with suboptimal treatment. In 54.8% of treatment-failing patients one of the causes of failure might be the presence of RASs. In the majority of patients with RASs, mutations were present at baseline. Direct resistance test is advocated before treatment and at breakthrough in order to optimize retreatment regimens.<\/jats:p>","DOI":"10.1038\/s41598-017-15987-1","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T10:47:49Z","timestamp":1510829269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs"],"prefix":"10.1038","volume":"7","author":[{"given":"Stefania","family":"Paolucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Premoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Novati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Maserati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Barbarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Sassera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leone","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Girello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario U.","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"15987_CR1","unstructured":"WHO Guidelines on Hepatitis B and C Testing Geneva: World Health Organization; Feb.ISBN-13: 978-92-4-154998-1 (2017)."},{"key":"15987_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology \n                           61, 77\u201387 (2015).","journal-title":"Hepatology"},{"key":"15987_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","volume":"13","author":"K Deterding","year":"2013","unstructured":"Deterding, K. et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect. Dis. \n                           13, 497\u2013506 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"15987_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"CJ Sarrazin","year":"2016","unstructured":"Sarrazin, C. J. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. \n                           64, 486\u2013504 (2016).","journal-title":"J. Hepatol."},{"key":"15987_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","volume":"17","author":"L Ben\u00edtez-Guti\u00e9rrez","year":"2016","unstructured":"Ben\u00edtez-Guti\u00e9rrez, L. et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin. Pharmacother. \n                           17, 1215\u201323 (2016).","journal-title":"Expert Opin. Pharmacother."},{"key":"15987_CR6","doi-asserted-by":"publisher","unstructured":"Chan, H. L. et al. Real-Life Efficacy and Safety of Paritaprevir\/Ritonavir, Ombitasvir and Dasabuvir in Chronic Hepatitis C Patients in Hong Kong. J. Gastroenterol. Hepatol. Nov 21; https:\/\/doi.org\/10.1111\/jgh.13663 [Epub ahead of print] (2016).","DOI":"10.1111\/jgh.13663"},{"key":"15987_CR7","first-page":"55","volume":"28","author":"A Alexopoulou","year":"2015","unstructured":"Alexopoulou, A. & Karayiannis, P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann. Gastroenterol. \n                           28, 55\u201365 (2015).","journal-title":"Ann. Gastroenterol."},{"key":"15987_CR8","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.3748\/wjg.v22.i35.8050","volume":"22","author":"CR Werner","year":"2016","unstructured":"Werner, C. R. et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J. Gastroenterol. \n                           22, 8050\u20138059 (2016).","journal-title":"World J. Gastroenterol."},{"key":"15987_CR9","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky, J. M., Feld, J. J., Zeuzem, S. & Hoofnagle, J. H. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. \n                           62, S87\u2013S99 (2015).","journal-title":"J. Hepatol."},{"key":"15987_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2893.2010.01367.x","volume":"18","author":"V Morel","year":"2011","unstructured":"Morel, V. et al. Genetic recombination of the hepatitis C virus: clinical implications. J. Viral. Hepat. \n                           18, 77\u201383 (2011).","journal-title":"J. Viral. Hepat."},{"key":"15987_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1586\/egh.09.60","volume":"3","author":"C Fran\u00e7ois","year":"2009","unstructured":"Fran\u00e7ois, C., Castelain, S., Duverlie, G., Capron, D. & Nguyen-Khac, E. Optimizing the treatment of chronic viral hepatitis C. Expert Rev. Gastroenterol. Hepatol. \n                           3, 607\u2013613 (2009).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"15987_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith, D. B. et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology \n                           59, 318\u2013327 (2014).","journal-title":"Hepatology"},{"key":"15987_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/hep.27934","volume":"62","author":"E Lontok","year":"2015","unstructured":"Lontok, E. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology \n                           62, 1623\u20131632 (2015).","journal-title":"Hepatology"},{"key":"15987_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1743-422X-9-245","volume":"9","author":"S Paolucci","year":"2012","unstructured":"Paolucci, S. et al. Naturally occurring mutations to HCV protease inhibitors in treatment-na\u00efve patients. Virol. J. \n                           9, 245, https:\/\/doi.org\/10.1186\/1743-422X-9-245 (2012).","journal-title":"Virol. J."},{"key":"15987_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/1743-422X-10-355","volume":"10","author":"S Paolucci","year":"2013","unstructured":"Paolucci, S. et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients. Virol. J. \n                           10, 355, https:\/\/doi.org\/10.1186\/1743-422X-10:355 (2013).","journal-title":"Virol. J."},{"key":"15987_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky, J. M. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology \n                           151, 70\u201386 (2016).","journal-title":"Gastroenterology"},{"key":"15987_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jcv.2015.08.015","volume":"72","author":"S Paolucci","year":"2015","unstructured":"Paolucci, S. et al. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. J Clin. Virol. \n                           72, 114\u20138 (2015).","journal-title":"J Clin. Virol."},{"key":"15987_CR18","doi-asserted-by":"crossref","unstructured":"Schuermans, W. et al. Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k\/1b Circulating Recombinant Form. Int. J. Mol. Sci. 23 17:Pii\u2009=\u2009E1384 (2016).","DOI":"10.3390\/ijms17091384"},{"key":"15987_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson, D. R. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology \n                           61, 1127\u20131135 (2015).","journal-title":"Hepatology"},{"key":"15987_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/liv.13327","volume":"37","author":"VC Di Maio","year":"2017","unstructured":"Di Maio, V. C. et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver. Int. \n                           37, 514\u2013528 (2017).","journal-title":"Liver. Int."},{"key":"15987_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology \n                           151, 501\u2013512 (2016).","journal-title":"Gastroenterology"},{"key":"15987_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","volume":"66","author":"D Wyles","year":"2017","unstructured":"Wyles, D. et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir. J. Hepatol. \n                           66, 703\u2013710 (2017).","journal-title":"J. Hepatol."},{"key":"15987_CR23","first-page":"S219","volume":"62","author":"E Lawitz","year":"2015","unstructured":"Lawitz, E., Flamm, S. & Yang, J. Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir\/Sofosbuvir-Based Regimens With Ledipasvir\/Sofosbuvir for 24 Weeks (abstr). J. Hepatol. \n                           62, S219 (2015).","journal-title":"J. Hepatol."},{"key":"15987_CR24","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents. Chemother. \n                           56, 3359\u20133368 (2012).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"15987_CR25","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00705-015-2533-9","volume":"160","author":"XD Cheng","year":"2015","unstructured":"Cheng, X. D., Xu, H. F., Wei, X. M. & Zhou, H. Z. Variation analysis of E1 and E2 in HCV subtypes. Arch. Virol. \n                           160, 2479\u20132482 (2015).","journal-title":"Arch. Virol."},{"key":"15987_CR26","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2013","unstructured":"Bartels, D. J. et al. Hepatitis C virus variants with decreased sensitivity to directacting antivirals (DAAs) were rarely observed in DAA naive patients prior to treatment. J. Virol. \n                           87, 1544\u20131553 (2013).","journal-title":"J. Virol."},{"key":"15987_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki, F. et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J. Clin. Virol. \n                           54, 352\u2013354 (2012).","journal-title":"J. Clin. Virol."},{"key":"15987_CR28","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/eji.201646581","volume":"46","author":"M Hofmann","year":"2016","unstructured":"Hofmann, M. & Thimme, R. MAIT be different-persisting dysfunction after DAA mediated clearance of chronic hepatitis C virus infection. Eur. J. Immunol. \n                           46, 2099\u20132102 (2016).","journal-title":"Eur. J. Immunol."},{"key":"15987_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hep.28422","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz, E. et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 147 study (OPTIMIST-2). Hepatology \n                           64, 360\u2013369 (2016).","journal-title":"Hepatology"},{"key":"15987_CR30","doi-asserted-by":"publisher","unstructured":"Jacobson, I.M. et al. Safety and Efficacy of Elbasvir\/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology pii: S0016-5085(17)30150-6; https:\/\/doi.org\/10.1053\/j.gastro.2017.01.050 [Epub ahead of print] (2017).","DOI":"10.1053\/j.gastro.2017.01.050"},{"key":"15987_CR31","doi-asserted-by":"publisher","unstructured":"Lawitz, E. et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV. Hepatology., doi: https:\/\/doi.org\/10.1002\/hep.29130 [Epub ahead of print] (2017).","DOI":"10.1002\/hep.29130"},{"key":"15987_CR32","doi-asserted-by":"crossref","unstructured":"European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 63, 199\u2013236 (2015).","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"15987_CR33","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1128\/AAC.00763-16","volume":"60","author":"EJ Lawitz","year":"2016","unstructured":"Lawitz, E. J. et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5AProtein. Antimicrob. Agents. Chemother. \n                           60, 5368\u20135378 (2016).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"15987_CR34","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1128\/AEM.01541-09","volume":"75","author":"PD Schloss","year":"2009","unstructured":"Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. \n                           75, 7537\u20137541 (2009).","journal-title":"Appl. Environ. Microbiol."},{"key":"15987_CR35","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"L Heng","year":"2009","unstructured":"Heng, L. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics \n                           25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15987-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:54:02Z","timestamp":1671803642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15987-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-15987-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]},"assertion":[{"value":"22 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16017"}}